Long-term secukinumab efficacy and safety in bio-naïve patients with moderate-to-severe cutaneous psoriasis: A real-world retrospective noninterventional multicentric experience (128 patients)
Background: There is limited evidence over the real-life secukinumab survival in psoriatic patients, especially in the long-term bio-na & iuml;ve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that ea...
| Autores: | , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p17119 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/17119 |
| Access Level: | acceso abierto |
| Palabra clave: | bio-na & iuml ve IL-17 inhibitors psoriasis real-world experience secukinumab |
| Sumario: | Background: There is limited evidence over the real-life secukinumab survival in psoriatic patients, especially in the long-term bio-na & iuml;ve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early intensive treatment with biological therapies could decrease pathogenic tissue resident memory (TRm) cells migration and potentially modify the natural course of psoriasis and related comorbidities. Objectives: To analyze long-term secukinumab efficacy, safety and survival, and its predictive factors for psoriasis treatment determining also whether early intervention may result in better outcomes for patients. Methods: Bio-na & iuml;ve psoriatic patients under treatment with secukinumab (n = 128 patients) in a daily practice setting were analyzed in a retrospective multicentric study and followed up to 8 years. Drug survival rate, efficacy, posology and safety were reported. Results: The overall secukinumab survival was 81.9% for an average treatment exposure of 147.9 weeks. The approved posology was the most commonly prescribed regimen (78.7%), and 17.7% could be optimized. An absolut-PASI <= 3 was reached by 86.6%, 82.6% and 91.7% at the weeks 48,156 and 264, respectively. The incidence of arthritis or psoriasis related comorbidities was low. The response was not influenced by weight, age (>65), gender or the presence of arthritis. No severe adverse events were reported. Conclusions: In our bio-na & iuml;ve series, the high efficacy and long-term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed. |
|---|